Clinical efficacy and controversies of aducanumab

Qingyue Gao

doi:10.1117/12.2692200

7 September 2023 Clinical efficacy and controversies of aducanumab

Qingyue Gao

Proceedings Volume 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023); 127892X (2023) https://doi.org/10.1117/12.2692200
Event: International Conference on Modern Medicine and Global Health (ICMMGH 2023), 2023, Oxford, United Kingdom

Abstract

The anti-amyloid monoclonal antibody aducanumab has been approved by FDA in Jun 2021. It is the first diseasemodifying drug for the treatment of mild Alzheimer’s Disease (AD) to improve cognitive functions by clearing the amyloid plaques in brain. This review discussed all aspects of the aducanumab development, including the structural and kinetic perspective in its discovery, the most important results from phase 1 and two phase 3 clinical trials and its controversies. Despite FDA approval, aducanumab did not announce a success in controlling the development of AD at early-stages possibly due to the contribution from other confounding pathological pathways and mixed biomarkers occurred during AD pathogenesis. Thereby, it is vital to conduct long-term post-market surveillance, as well as concentrating more on researching AD pathogenesis. Other potential therapeutic targets, such as inhibiting unfolded protein response (UPR) signaling pathways, might also contribute to the progression of AD and therefore catch increasing attention in research field.

Citation Download Citation

Qingyue Gao "Clinical efficacy and controversies of aducanumab", Proc. SPIE 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023), 127892X (7 September 2023); https://doi.org/10.1117/12.2692200

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available